Last reviewed · How we verify

NCT04220268: GGN-F

A Prospective Cohort of Pulmonary Ground Glass Nodules Patients With Family History.

Status unknown Last updated 7 January 2020
What this trial tests

trial in Lung Neoplasms in 600 participants. Status unknown.

Timeline
5 January 2020
Primary endpoint
5 January 2022
31 January 2022

Quick facts

Lead sponsorGuangdong Provincial People's Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment600
Start date5 January 2020
Primary completion5 January 2022
Estimated completion31 January 2022
Sites1 location across China

Conditions studied

Sponsor

Guangdong Provincial People's Hospital

Who can join

Eligibility, any sex, with Lung Neoplasms or Family Research. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present prospective cohort study (GGN-F) is to study the family aggregation of pulmonary ground glass nodules via the questionnaire survey and to investigate the underlying genetic mechanism via the biobank.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04220268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing